ATE438859T1 - Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz - Google Patents

Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz

Info

Publication number
ATE438859T1
ATE438859T1 AT04764350T AT04764350T ATE438859T1 AT E438859 T1 ATE438859 T1 AT E438859T1 AT 04764350 T AT04764350 T AT 04764350T AT 04764350 T AT04764350 T AT 04764350T AT E438859 T1 ATE438859 T1 AT E438859T1
Authority
AT
Austria
Prior art keywords
insulin resistance
inhibition
kinase activity
treat insulin
kinase
Prior art date
Application number
AT04764350T
Other languages
English (en)
Inventor
Johan Auwerx
Francesca Frigerio
Stefano Fumagalli
Sara Kozma
Frederic Picard
Melanie Sticker-Jantscheff
George Thomas
Sung Um
Mitsuhiro Watanabe
Original Assignee
Novartis Forschungsstiftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Forschungsstiftung filed Critical Novartis Forschungsstiftung
Application granted granted Critical
Publication of ATE438859T1 publication Critical patent/ATE438859T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04764350T 2003-08-22 2004-08-20 Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz ATE438859T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49722603P 2003-08-22 2003-08-22
PCT/EP2004/009368 WO2005019829A1 (en) 2003-08-22 2004-08-20 Inhibition of s6 kinase activity for the treatment of insulin resistance

Publications (1)

Publication Number Publication Date
ATE438859T1 true ATE438859T1 (de) 2009-08-15

Family

ID=34216100

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04764350T ATE438859T1 (de) 2003-08-22 2004-08-20 Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz

Country Status (7)

Country Link
US (1) US20070191259A1 (de)
EP (1) EP1658504B1 (de)
JP (1) JP2007503203A (de)
AT (1) ATE438859T1 (de)
DE (1) DE602004022423D1 (de)
ES (1) ES2331006T3 (de)
WO (1) WO2005019829A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020755A2 (en) * 2004-08-10 2006-02-23 Beth Israel Deaconess Medical Center, Inc. Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics
US7919472B2 (en) * 2004-09-17 2011-04-05 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
US7897595B2 (en) * 2006-05-26 2011-03-01 Forest Laboratories Holdings Limited Pyridoazepine derivatives
CA2669687C (en) 2006-11-15 2013-09-10 Forest Laboratories Holdings Limited Phthalazine derivatives
CN110898225A (zh) * 2019-12-23 2020-03-24 黑龙江中医药大学 mTOR/S6K1及MAPK信号通路抑制在胰岛素抵抗改善中的应用
CN116322773A (zh) * 2020-04-21 2023-06-23 马萨诸塞大学 用于治疗年龄相关性黄斑变性的方法和组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US20030083284A1 (en) * 2001-08-01 2003-05-01 Isis Pharmaceuticals Inc. Antisense modulation of p70 S6 kinase expression
WO2001044497A2 (en) * 1999-12-02 2001-06-21 University Of Dundee Protein kinase regulation
GB0224338D0 (en) * 2002-10-18 2002-11-27 Novartis Forschungsstiftung Modulation of S6 kinase activity for the treatment of obesity

Also Published As

Publication number Publication date
ES2331006T3 (es) 2009-12-18
WO2005019829A1 (en) 2005-03-03
DE602004022423D1 (de) 2009-09-17
US20070191259A1 (en) 2007-08-16
EP1658504B1 (de) 2009-08-05
EP1658504A1 (de) 2006-05-24
JP2007503203A (ja) 2007-02-22

Similar Documents

Publication Publication Date Title
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE60312516D1 (de) Inhibitoren von mitotischem kinesin
ATE421512T1 (de) Inhibitoren von mitotischem kinesin
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
ATE446094T1 (de) Mitotische kinesin-hemmer
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE448207T1 (de) Mitotische kinesin-hemmer
ATE424388T1 (de) Mitotische kinesinhemmer
ATE447577T1 (de) Mitotische kinesin-hemmer
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
ATE387194T1 (de) Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung
DE602004004883D1 (de) Vegf-antagonisten zur behandlung von diabetes
ATE424208T1 (de) Proteinkinaseinhibitoren
ATE438859T1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
ATE426605T1 (de) Inhibitoren von mitotischem kinesin
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
DE60327793D1 (de) Modulation der s6-kinaseaktivität zur behandlung von adipositas
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
ATE482218T1 (de) Inhibitoren von mitotischem kinesin
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
DE602004017425D1 (de) Pmcol zur behandlung von prostatakrebs
ATE427754T1 (de) Verwendung von il-17f zur behandlung und/oder pravention von neurologischen erkrankungen
ATE350034T1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus
ATE535246T1 (de) Zusammensetzung zur behandlung von erkrankungen des zentralen nervensystems

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1658504

Country of ref document: EP

REN Ceased due to non-payment of the annual fee